HK1215873A1 - 調整代謝紊亂的方法及組合物 - Google Patents
調整代謝紊亂的方法及組合物 Download PDFInfo
- Publication number
- HK1215873A1 HK1215873A1 HK16103861.2A HK16103861A HK1215873A1 HK 1215873 A1 HK1215873 A1 HK 1215873A1 HK 16103861 A HK16103861 A HK 16103861A HK 1215873 A1 HK1215873 A1 HK 1215873A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- metabolic disorders
- regulation
- compositions
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261733652P | 2012-12-05 | 2012-12-05 | |
| US61/733,652 | 2012-12-05 | ||
| PCT/US2013/073119 WO2014089212A1 (en) | 2012-12-05 | 2013-12-04 | Methods and compositions for regulation of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1215873A1 true HK1215873A1 (zh) | 2016-09-23 |
Family
ID=50826041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16103861.2A HK1215873A1 (zh) | 2012-12-05 | 2013-12-04 | 調整代謝紊亂的方法及組合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9255250B2 (zh) |
| EP (1) | EP2929017A4 (zh) |
| JP (1) | JP2016500254A (zh) |
| AU (1) | AU2013355327A1 (zh) |
| CA (1) | CA2892448A1 (zh) |
| HK (1) | HK1215873A1 (zh) |
| WO (1) | WO2014089212A1 (zh) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| MX363017B (es) * | 2012-11-01 | 2019-03-04 | Factor Bioscience Inc | Métodos y productos para la expresión de proteínas en células. |
| JP2016518142A (ja) * | 2013-05-10 | 2016-06-23 | サンガモ バイオサイエンシーズ， インコーポレイテッド | ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法および組成物 |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9834791B2 (en) | 2013-11-07 | 2017-12-05 | Editas Medicine, Inc. | CRISPR-related methods and compositions with governing gRNAS |
| US20150166985A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting von willebrand factor point mutations |
| WO2015127439A1 (en) | 2014-02-24 | 2015-08-27 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration |
| WO2015164778A1 (en) * | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennysylvania | Ldlr variants and their use in compositions for reducing cholesterol levels |
| EP4079847A1 (en) | 2014-07-30 | 2022-10-26 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| JP6800859B2 (ja) | 2015-01-26 | 2020-12-16 | フェイト セラピューティクス，インコーポレイテッド | 造血細胞分化を誘導するための方法および組成物 |
| US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
| CA2988854A1 (en) | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
| JP6873917B2 (ja) | 2015-05-12 | 2021-05-19 | サンガモ セラピューティクス， インコーポレイテッド | ヌクレアーゼ介在性遺伝子発現調節 |
| US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
| US11980663B2 (en) | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| CN108024544B (zh) | 2015-07-13 | 2022-04-29 | 桑格摩生物治疗股份有限公司 | 用于核酸酶介导的基因组工程化的递送方法及组合物 |
| IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and uses thereof |
| AU2016343887B2 (en) | 2015-10-28 | 2023-04-06 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
| ES2953925T3 (es) | 2015-11-04 | 2023-11-17 | Fate Therapeutics Inc | Ingeniería genómica de células pluripotentes |
| US10858628B2 (en) | 2015-11-04 | 2020-12-08 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CA2999649A1 (en) * | 2015-11-06 | 2017-05-11 | Crispr Therapeutics Ag | Materials and methods for treatment of glycogen storage disease type 1a |
| AU2016361350B2 (en) | 2015-11-23 | 2023-04-06 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
| US11510998B2 (en) * | 2015-12-11 | 2022-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene therapy for combined methylmalonic acidemia/aciduria and hyperhomocysteinemia/homocystinuria, cobalamin C type, and deficiency of MMACHC |
| CA3007108A1 (en) | 2015-12-17 | 2017-06-22 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| EA201891212A1 (ru) | 2015-12-18 | 2019-01-31 | Сангамо Терапьютикс, Инк. | Адресная дезорганизация клеточного рецептора гкгс |
| WO2017106528A2 (en) | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the t cell receptor |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| WO2017123918A1 (en) | 2016-01-15 | 2017-07-20 | American Gene Technologies International Inc. | Methods and compositons for the activation of gamma-delta t-cells |
| KR20180127319A (ko) | 2016-01-15 | 2018-11-28 | 상가모 테라퓨틱스, 인코포레이티드 | 신경 질환의 치료를 위한 방법 및 조성물 |
| CN109069568B (zh) | 2016-02-02 | 2023-07-07 | 桑格摩生物治疗股份有限公司 | 用于连接dna结合结构域和切割结构域的组合物 |
| US10888613B2 (en) | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
| US10767183B2 (en) | 2016-03-09 | 2020-09-08 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| WO2017201349A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
| EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS |
| IL300730A (en) | 2016-07-08 | 2023-04-01 | American Gene Tech Int Inc | Pre-HIV vaccine and immunotherapy |
| EP3487507A4 (en) | 2016-07-21 | 2020-04-08 | American Gene Technologies International, Inc. | VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE |
| US11883470B2 (en) | 2016-07-25 | 2024-01-30 | The Trustees Of The University Of Pennsylvania | Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof |
| EP3491134B1 (en) * | 2016-08-01 | 2023-10-11 | University of Pittsburgh - of The Commonwealth System of Higher Education | Human induced pluripotent stem cells for high efficiency genetic engineering |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| CA3034884A1 (en) | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
| BR112019003100A2 (pt) | 2016-08-24 | 2019-07-09 | Sangamo Therapeutics Inc | regulação da expressão gênica usando nucleases manipuladas |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| JP7256739B2 (ja) * | 2016-09-07 | 2023-04-12 | サンガモ セラピューティクス， インコーポレイテッド | 肝臓遺伝子のモジュレーション |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| JP7042263B2 (ja) | 2016-10-20 | 2022-03-25 | サンガモ セラピューティクス， インコーポレイテッド | ファブリー病の治療のための方法および組成物 |
| JP2020500539A (ja) * | 2016-12-09 | 2020-01-16 | サンガモ セラピューティクス， インコーポレイテッド | 標的特異的ヌクレアーゼの送達 |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| EP3595688A4 (en) | 2017-02-20 | 2020-12-30 | The Trustees Of The University Of Pennsylvania | GENE THERAPY TO TREAT FAMILY HYPERCHOLESTEROLEMIA |
| AU2018224380A1 (en) * | 2017-02-22 | 2019-08-29 | Crispr Therapeutics Ag | Compositions and methods for treatment of proprotein convertase subtilisin/kexin type 9 (PCSK9)-related disorders |
| US11407997B2 (en) | 2017-02-22 | 2022-08-09 | Crispr Therapeutics Ag | Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| CN108660156A (zh) * | 2017-03-16 | 2018-10-16 | 中国人民解放军军事科学院军事医学研究院 | Cps1报告基因干细胞及其构建方法与应用 |
| GB2575930A (en) | 2017-03-23 | 2020-01-29 | Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| WO2018187231A2 (en) * | 2017-04-03 | 2018-10-11 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| US20200197442A1 (en) * | 2017-04-26 | 2020-06-25 | Nsage Corp. | Pharmaceutical composition for prevention or treatment of alzheimer's disease, comprising stem cell secreting srage |
| CA3061612A1 (en) | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| AU2018352592B2 (en) | 2017-10-16 | 2025-03-27 | Beam Therapeutics, Inc. | Uses of adenosine base editors |
| US20220265856A1 (en) * | 2017-11-22 | 2022-08-25 | Modernatx, Inc. | Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia |
| CN111699290A (zh) * | 2018-01-31 | 2020-09-22 | 丝芭博株式会社 | 蛋白质卷曲短纤维的制造方法 |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| WO2019152843A1 (en) | 2018-02-01 | 2019-08-08 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof |
| WO2019157324A1 (en) | 2018-02-08 | 2019-08-15 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
| EP3755795A4 (en) | 2018-02-19 | 2022-07-20 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof |
| CN112585277A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 表达重组受体的t细胞、相关多核苷酸和方法 |
| MA52656A (fr) | 2018-04-05 | 2021-02-17 | Editas Medicine Inc | Procédés de production de cellules exprimant un récepteur recombinant et compositions associées |
| WO2020009740A2 (en) * | 2018-04-25 | 2020-01-09 | Washington University | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders |
| US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
| EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
| SG11202012499RA (en) | 2018-06-28 | 2021-01-28 | Crispr Therapeutics Ag | Compositions and methods for genomic editing by insertion of donor polynucleotides |
| EP3841204A4 (en) | 2018-08-23 | 2022-05-18 | Sangamo Therapeutics, Inc. | CHANGED TARGET SPECIFIC BASE EDITORS |
| WO2020061161A1 (en) | 2018-09-18 | 2020-03-26 | Sangamo Therapeutics, Inc. | Programmed cell death 1 (pd1) specific nucleases |
| WO2020061426A2 (en) | 2018-09-21 | 2020-03-26 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
| GB2593353B (en) | 2018-10-16 | 2023-03-01 | Blueallele Corp | Methods for targeted insertion of DNA in genes |
| SG11202103734PA (en) | 2018-10-18 | 2021-05-28 | Intellia Therapeutics Inc | Compositions and methods for expressing factor ix |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| JP2022506515A (ja) | 2018-11-05 | 2022-01-17 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | 制御性ｒｎａを発現させるためのベクターシステム |
| CN109468372B (zh) * | 2018-11-21 | 2020-08-04 | 中国人民解放军陆军军医大学第一附属医院 | 多种遗传代谢性肝病靶向文库的引物组合、方法及试剂盒 |
| PT3908568T (pt) | 2019-01-11 | 2024-09-30 | Acuitas Therapeutics Inc | Lípidos para a administração de agentes ativos por nanopartículas lipídicas |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| JP7669281B2 (ja) | 2019-03-19 | 2025-04-28 | ザ ブロード インスティテュート，インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
| US12281323B2 (en) | 2019-04-15 | 2025-04-22 | The Regents Of The University Of California | Treatment for restoring ureagenesis in carbamoyl phosphate synthetase 1 deficiency |
| AU2020265741A1 (en) | 2019-05-01 | 2021-11-25 | Editas Medicine, Inc. | Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods |
| AU2020265749A1 (en) | 2019-05-01 | 2022-01-06 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods |
| BR112021022722A2 (pt) | 2019-06-07 | 2022-01-04 | Regeneron Pharma | Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| EP4150057A2 (en) | 2020-05-13 | 2023-03-22 | Juno Therapeutics, Inc. | Process for producing donor-batched cells expressing a recombinant receptor |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| CN111693715A (zh) * | 2020-06-17 | 2020-09-22 | 山东省医学科学院基础医学研究所 | 一种线粒体中单磷酸尿苷酸化修饰蛋白的筛选方法及其应用 |
| JP2023531531A (ja) | 2020-06-26 | 2023-07-24 | ジュノ セラピューティクス ゲーエムベーハー | 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法 |
| KR20230051172A (ko) | 2020-07-16 | 2023-04-17 | 아퀴타스 테라퓨틱스 인크. | 지질 나노 입자에 사용하기 위한 양이온성 지질 |
| US11332744B1 (en) | 2020-10-26 | 2022-05-17 | Arsenal Biosciences, Inc. | Safe harbor loci |
| JP2023547887A (ja) * | 2020-10-26 | 2023-11-14 | アーセナル バイオサイエンシズ インコーポレイテッド | セーフハーバー遺伝子座 |
| EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
| TW202302846A (zh) * | 2021-04-16 | 2023-01-16 | 中國大陸商杭州啟函生物科技有限公司 | 用於細胞工程化的安全港基因座 |
| MX2024003887A (es) | 2021-10-14 | 2024-07-09 | Arsenal Biosciences Inc | Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. |
| WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| WO2024161021A1 (en) | 2023-02-03 | 2024-08-08 | Juno Therapeutics Gmbh | Methods for non-viral manufacturing of engineered immune cells |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| AU704601B2 (en) | 1994-01-18 | 1999-04-29 | Scripps Research Institute, The | Zinc finger protein derivatives and methods therefor |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| DE69535829D1 (de) | 1994-08-20 | 2008-10-16 | Gendaq Ltd | Verbesserung in bezug auf bindungsproteine bei der erkennung von dna |
| US5856152A (en) * | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| DE69942334D1 (de) | 1998-03-02 | 2010-06-17 | Massachusetts Inst Technology | Poly-zinkfinger-proteine mit verbesserten linkern |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
| IL150069A0 (en) | 1999-12-06 | 2002-12-01 | Sangamo Biosciences Inc | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| EP1254369B1 (en) | 2000-02-08 | 2010-10-06 | Sangamo BioSciences, Inc. | Cells for drug discovery |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| WO2003016496A2 (en) | 2001-08-20 | 2003-02-27 | The Scripps Research Institute | Zinc finger binding domains for cnn |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| BRPI0307383B1 (pt) | 2002-01-23 | 2019-12-31 | The Univ Of Utah Research Foundation | método de recombinação genética direcionada em célula de planta hospedeira |
| AU2003218382B2 (en) | 2002-03-21 | 2007-12-13 | Sangamo Therapeutics, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| JP2006502748A (ja) | 2002-09-05 | 2006-01-26 | カリフォルニア インスティテュート オブ テクノロジー | 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法 |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| ES2315859T3 (es) | 2004-04-08 | 2009-04-01 | Sangamo Biosciences, Inc. | Metodos y composiciones para tratar afecciones neuropaticas y neurodegenerativas. |
| CA2562193A1 (en) | 2004-04-08 | 2005-10-27 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
| EP2292274A1 (en) | 2004-09-16 | 2011-03-09 | Sangamo BioSciences, Inc. | Compositions and methods for protein production |
| EP1877583A2 (en) | 2005-05-05 | 2008-01-16 | Arizona Board of Regents on behalf of the Unversity of Arizona | Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences |
| US20100055793A1 (en) * | 2005-07-25 | 2010-03-04 | Johns Hopkins University | Site-specific modification of the human genome using custom-designed zinc finger nucleases |
| KR20080033455A (ko) | 2005-07-26 | 2008-04-16 | 상가모 바이오사이언스 인코포레이티드 | 외래 핵산 서열의 표적화된 통합 및 발현 |
| AU2007267874B2 (en) | 2006-05-25 | 2012-03-15 | Sangamo Therapeutics, Inc. | Methods and compositions for gene inactivation |
| DE602007005634D1 (de) | 2006-05-25 | 2010-05-12 | Sangamo Biosciences Inc | Variante foki-spaltungshälften-domänen |
| EP2089427B1 (en) * | 2006-11-13 | 2014-07-30 | Sangamo BioSciences, Inc. | Zinc finger nuclease for targeting the human glucocorticoid receptor locus |
| ATE489465T1 (de) * | 2007-04-26 | 2010-12-15 | Sangamo Biosciences Inc | Gezielte integration in die ppp1r12c-position |
| US8790345B2 (en) | 2007-08-21 | 2014-07-29 | Zimmer, Inc. | Titanium alloy with oxidized zirconium for a prosthetic implant |
| EP2188384B1 (en) | 2007-09-27 | 2015-07-15 | Sangamo BioSciences, Inc. | Rapid in vivo identification of biologically active nucleases |
| EP2281050B1 (en) | 2008-04-14 | 2014-04-02 | Sangamo BioSciences, Inc. | Linear donor constructs for targeted integration |
| JP5908725B2 (ja) | 2008-08-22 | 2016-04-26 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 標的一本鎖開裂および標的組込みのための方法、並びに組成物 |
| JP5681114B2 (ja) | 2008-12-04 | 2015-03-04 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 亜鉛フィンガーヌクレアーゼを使用したラットのゲノム編集 |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| WO2010117464A1 (en) * | 2009-04-09 | 2010-10-14 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
| KR20120097483A (ko) * | 2009-07-24 | 2012-09-04 | 시그마-알드리치 컴퍼니., 엘엘씨 | 게놈 편집을 위한 방법 |
| EP3456826B1 (en) * | 2009-12-10 | 2023-06-28 | Regents of the University of Minnesota | Tal effector-mediated dna modification |
| WO2011097036A1 (en) | 2010-02-08 | 2011-08-11 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
| EP2660318A1 (en) | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| JP2013520190A (ja) * | 2010-02-26 | 2013-06-06 | セレクティス | セーフハーバー遺伝子座への導入遺伝子の挿入のためのエンドヌクレアーゼの使用 |
| US9567573B2 (en) | 2010-04-26 | 2017-02-14 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using nucleases |
| EP3156062A1 (en) * | 2010-05-17 | 2017-04-19 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
| US9057057B2 (en) * | 2010-07-27 | 2015-06-16 | The Johns Hopkins University | Obligate heterodimer variants of foki cleavage domain |
| JP6018069B2 (ja) * | 2010-10-12 | 2016-11-02 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | 血友病ｂを治療する方法及び組成物 |
| US9394545B2 (en) * | 2011-09-21 | 2016-07-19 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
| CA2852955C (en) | 2011-10-27 | 2021-02-16 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
| EP3730615A3 (en) | 2013-05-15 | 2020-12-09 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
-
2013
- 2013-12-04 CA CA2892448A patent/CA2892448A1/en not_active Abandoned
- 2013-12-04 EP EP13859888.3A patent/EP2929017A4/en not_active Withdrawn
- 2013-12-04 AU AU2013355327A patent/AU2013355327A1/en not_active Abandoned
- 2013-12-04 HK HK16103861.2A patent/HK1215873A1/zh unknown
- 2013-12-04 JP JP2015545822A patent/JP2016500254A/ja active Pending
- 2013-12-04 US US14/096,788 patent/US9255250B2/en active Active
- 2013-12-04 WO PCT/US2013/073119 patent/WO2014089212A1/en active Application Filing
-
2016
- 2016-01-28 US US15/009,517 patent/US20160143953A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140155468A1 (en) | 2014-06-05 |
| WO2014089212A1 (en) | 2014-06-12 |
| EP2929017A4 (en) | 2016-09-28 |
| CA2892448A1 (en) | 2014-06-12 |
| US9255250B2 (en) | 2016-02-09 |
| JP2016500254A (ja) | 2016-01-12 |
| AU2013355327A1 (en) | 2015-06-11 |
| EP2929017A1 (en) | 2015-10-14 |
| US20160143953A1 (en) | 2016-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1215873A1 (zh) | 調整代謝紊亂的方法及組合物 | |
| IL263324A (en) | Methods and preparations for regulating transgene expression | |
| IL264455A (en) | Progenitor cells of mesodermal lineage | |
| EP3119798A4 (en) | Compositions and methods for enhanced gene expression in cone cells | |
| EP2928496A4 (en) | Crispr-based genome modification and regulation | |
| ZA201309287B (en) | Methods and compositions for selective regulation of protein expression | |
| SG10201610915XA (en) | Methods and compositions for natural killer cells | |
| ZA201502928B (en) | Reduction of gassing in lithium titanate cells | |
| EP3215139A4 (en) | Compositions and methods for improved car-t cell therapies | |
| IL227919A0 (en) | Methods and preparations for the production of stem cells related to highly active nerve cells specific to the patient | |
| PL2736648T3 (pl) | Wirówka oraz człon odprowadzający wirówki do zmniejszania zużycia energii | |
| EP3237642A4 (en) | Compositions and methods for manipulation of adipocyte energy consumption regulatory pathway | |
| EP3030660A4 (en) | Composition for enhancing transgene expression in eukaryotic cells and method for enhancing production of a target protein encoded by a transgene | |
| EP3164127A4 (en) | Compositions and methods to improve adoptive cell therapies | |
| HK40103728A (zh) | 用於自然殺傷細胞的方法和組合物 | |
| HK40001091B (zh) | 基於crispr的基因組修飾和調控 | |
| HK1187952A (zh) | 產生患者特異性多能神經元幹細胞的方法和組合物 | |
| HK40006355A (zh) | 用於增强干細胞療法的方法和組合物 | |
| AU2012900572A0 (en) | Compositions and methods for the treatment of cystic fibrosis | |
| IL232758A0 (en) | Methods for increasing angiogenesis and preparations for performing them | |
| HK1192151A (zh) | 治療心血管疾病的組合物和方法 | |
| ZA201400696B (en) | Progenitor cells of mesodermal lineage | |
| HK1186561A (zh) | 在線繪畫的協作編輯 | |
| AU2011903938A0 (en) | Therapeutic methods and compositions |